Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-1558

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 500mg 70518 1558 01

Divalproex Sodium 500 mg delayed-release oral tablets in a bottle label showing quantity of 100 tablets. The label includes NDC 70518-1558-01 and indicates repackaging by RemedyRepack Inc. Directions reference the package insert; storage conditions are provided. Manufacturer is Sun Pharma, Cranbury, NJ.*

FDA Label Image

Divalproex Sodium 500mg 70518 1558 02

Divalproex Sodium 500 mg delayed-release tablet packaging label showing a single tablet quantity. The label displays the brand Remedy Repack, indicates RX only, and includes storage instructions and repackaging information by RemedyRepack Inc. Manufacturer is Sun Pharma, Cranbury, NJ.*

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium 500 mg delayed-release tablets packaging label showing a quantity of 30 tablets. The label includes manufacturer information indicating repackaging by RemedyRepack Inc, Indiana, and original manufacturing by Sun Pharma, Cranbury, NJ. Directions for use refer to the package insert, with storage temperature guidelines provided.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar graph labeled Figure 1 comparing the percentage results of two studies (Study 1 using YMRS and Study 2 using MRS) between Divalproex Sodium (DVPX) and placebo (PBO). Study 1 shows 26% for placebo and 60% for Divalproex Sodium, while Study 2 shows 29% for placebo and 58% for Divalproex Sodium.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A line graph labeled Figure 2 illustrating the percentage reduction in CPS rate versus percentage of patients for Divalproex Sodium (DVPX) delayed-release tablets and placebo. The y-axis shows percentage reduction in CPS rate from -100% to 100%, with improvement above zero and worsening below zero. The x-axis represents percentage of patients from 0 to 100. Two curves compare DVPX (solid line) and placebo (dashed line) across patient percentages.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A population curve graph titled Figure 3 showing % Reduction in CPS Rate (vertical axis) versus % of Patients (horizontal axis) for two groups: High Dose (solid line) and Low Dose (dashed line). The vertical axis ranges from -100% to 100%, indicating worsening to improvement, with a central line at 0% labeled No Change. The horizontal axis runs from 100% to 0%, showing cumulative patient percentages.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium (DVPX) groups in two separate studies. The vertical axis represents migraine rates, and the horizontal axis shows groups for Study 1 and Study 2, with placebo groups having higher migraine rates than DVPX groups in both studies.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure diagram of Divalproex Sodium, illustrating its molecular arrangement including sodium ion and organic groups. The image depicts the repeating unit of the molecule annotated with chemical bonds and atom groups as part of the polymeric complex.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.